UK markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Delayed price. Currency in EUR
Add to watchlist
10.02-0.86 (-7.86%)
At close: 05:35PM CEST

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • J
    JAM
    up 7
  • S
    SouP
    do it!!!
  • u
    user
    Grifols will make a big move soon. . .
  • l
    leonard
    Big article in STAT yesterday that the US multi-institutional consortium study on the benefits of convalescent plasma for sick patients with CV19 was strongly suggestive of efficacy; unfortunately, it was not a randomized placebo controlled study. The formal paper is awaiting publication. Under BARDA auspices, convalescent plasma is being converted into immunoglobulin(powder) which enables standardization from batch to batch, and allows for easier storage and administration. The GRFS product has already begun a ph3 study for CV19, both for prophylaxis for exposed individuals and as Rx for sick patients. The chances of success are excellent. The purest play on this theme is GRFS, which is a 15bil market cap biomedical company which specializes in plasma collection and plasma based theraputics. GRFS is one of the few biomedical companies which has failed to get a boost from CV19 and a +ph3 study almost certainly will lead to explosive growth. I am a heavy buyer today. Incidentally, I am a hematologist who did 2 years of immunology research on antibody therapy at NIH
  • l
    leonard
    GRFS. is in a good position as the largest plasma collector and already has a contract with BARDA:

    https://www.jwatch.org/

    Early Results Promising for Convalescent Plasma for COVID-19

    By Kelly Young

    Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

    A small, preliminary case series in JAMA shows promise for using convalescent plasma to treat critically ill patients with novel coronavirus disease (COVID-19).

    Researchers in China treated five COVID-19 patients who required mechanical ventilation and had severe pneumonia and high viral load despite taking antivirals. Plasma donors had recovered from SARS-CoV-2 infection and had been symptom-free for at least 10 days. Recipients received 400 mL of convalescent plasma containing neutralizing antibody.

    Within a day of the transfusion, markers of viral load began to improve. All patients saw gradual resolution of pulmonary lesions within 3 days. By day 9, four patients no longer required respiratory support. Three of the patients had been discharged after stays of roughly 50 days. The other two were still hospitalized.

    The authors and editorialists note that the results need to be validated in clinical trials. Last week, the FDA allowed physicians to apply for emergency use of investigational convalescent plasma to treat individual patients.

    LINK(S):

    JAMA article on convalescent plasma (Free)

    JAMA editorial (Free)

    FDA information on investigational convalescent plasma (Free)

    NEJM COVID-19 page (Free)
    NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
    NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
    www.jwatch.org
  • G
    Gary
    i just bought some shares. the earnings estimates are on the upswing and the company is at 52 week low. the dividend is nice and supportable. i think it is a good time to buy some shares.
  • J
    Jackson
    It's strange how people talk about all the profit they have been making through trading of Bitcoin while I'm here not making any profit at all.Can someone put me through on the right path.
  • N
    Nasdaq Quarterback
    I'm a true long here.. Been in the options for a long time. Based on my data this will move by Sept with a bigger move for November followed by Jan/Feb.
  • G
    Greg
    I bought GRFS today at 11.99. Seems cheap…. I think it will make a comeback. Might take some time but I’m in now.
  • G
    Gary
    from my readings, analysts dont like the stock because they are worried the company is over leveraged and took on too much debt. they are worried about the biotest acquisition as well. grfs needed to suspend the dividend to help shore up the balance sheet. ok - that is the negative side. on positive side, if they can successfully absorb biotest and generate a decent return on their investment, and shore up their balance sheet over the next year- this can turn out to be a decent investment. i think it is cheap turnaround play here. gl
  • A
    Alfonso
    I think this will go up tomorrow due to Trumps FDA plasma news
  • G
    Gary
    does grfs still pay a dividend? i haven't heard of a cut ..
  • A
    Alan
    A Singapore wealth fund becomes a strategic investor by investing $1 billion to acquire a minority stake in a Grifols subsidiary with 300 U.S. plasma centers that will remain under Grifols management
  • O
    O
    President Donald Trump on Sunday will announce the emergency authorization of convalescent plasma for Covid-19, according to the Washington Post and other reports.
    President Donald Trump on Sunday will announce the emergency authorization of convalescent plasma for Covid-19, according to the Washington Post and other reports.
    www.cnbc.com
  • G
    Gary
    some companies trading at nosebleed levels .this company is cheaply priced. why does it go lower? no sense at all
  • M
    Mi
    Seems like still in downtrend. Wait for a true reverse point to enter.